Anzeige
Mehr »
Dienstag, 13.05.2025 - Börsentäglich über 12.000 News
Titan für Raketen, Vanadium für Batterien: Radar-Projekt perfekt für die Industrie-Revolution!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DWEJ | ISIN: US15117N6022 | Ticker-Symbol: CBO
Tradegate
12.05.25 | 08:29
0,705 Euro
-3,42 % -0,025
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
IMUNON INC Chart 1 Jahr
5-Tage-Chart
IMUNON INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,7000,74012.05.
0,7050,75512.05.

Aktuelle News zur IMUNON Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoImunon outlines 40% trial cost reduction and early readout potential as OVATION 3 Phase III launches2
MoImunon, Inc. - 10-Q, Quarterly Report-
IMUNON Aktie jetzt für 0€ handeln
MoImunon GAAP EPS of -$0.282
MoImunon, Inc.: IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update84First site initiated for Phase 3 OVATION 3 study of IMNN-001 in treatment of newly diagnosed advanced ovarian cancer New data from Phase 2 OVATION 2 study of IMNN-001 accepted for oral presentation...
► Artikel lesen
MoImunon, Inc. - 8-K, Current Report-
FrImunon's Earnings: A Preview2
DoIMUNON treibt Phase-3-Studie für Eierstockkrebstherapie voran1
DoImunon, Inc.: IMUNON Announces First Site Initiated for Pivotal Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer110Company currently initiating additional trial sites and working with study investigators to enroll participants IMNN-001 is the first and only immunotherapy to show meaningful overall survival benefit...
► Artikel lesen
06.05.IMUNON to present OVATION 2 trial data at ASCO4
06.05.Imunon, Inc.: IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published ...94Data from OVATION 2 trial will also be reviewed in an oral presentation at ASCO Annual Meeting on June 3, 2025 LAWRENCEVILLE, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a...
► Artikel lesen
21.04.Imunon, Inc.: IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting5
04.04.Imunon files to sell 10M shares of common stock, warrants12
04.04.Imunon, Inc. - S-1, General form for registration of securities2
24.03.IMUNON advances to Phase 3 trial in ovarian cancer treatment5
24.03.Imunon, Inc.: IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer603First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer Initiation of trial sites underway for ground-breaking Phase 3...
► Artikel lesen
24.03.Imunon, Inc. - 8-K, Current Report-
28.02.H.C. Wainwright lifts Imunon stock target to $14 on Phase 3 plans13
27.02.Imunon, Inc.: IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study186IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer Patient enrollment in Phase 3 pivotal trial of IMNN-001 scheduled to begin in...
► Artikel lesen
27.02.Imunon, Inc. - 10-K, Annual Report-
27.02.Imunon, Inc. - 8-K, Current Report-
Seite:  Weiter >>
40 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1